INMUNE BIO INC

INMB refers to INmune Bio Inc., a clinical-stage biotechnology company. It focuses on developing therapies that target the innate immune system to treat cancer and chronic inflammation. Its pipeline includes product candidates designed to modulate immune responses, such as INKmune for natural killer cell therapy and XPro1595 for neuroinflammation. The company is research-oriented and does not currently market commercial products, so its progress depends heavily on clinical trial outcomes and regulatory milestones.

Recent performance for INMB is not fixed and changes with market trading. For the latest price movement, including daily and weekly changes, please refer to the live quote and performance chart on this page. Clinical-stage biotechnology stocks can be especially sensitive to news, so checking the most current data before drawing conclusions is important.

INMB stock can be influenced by clinical trial results, regulatory decisions, financing activities, and partnership announcements. Because it is a small-cap biotech with no approved products, sentiment around its pipeline and cash runway can drive volatility. Broader market conditions, interest rates, and sector rotation in biotechnology also play a role. Company-specific news often has an outsized effect compared with diversified large-cap stocks.

Valuation for INMB is unconventional because the company is clinical-stage and may not have meaningful revenue or earnings. Traditional metrics like the P/E ratio are often not applicable. Investors typically look at cash balances, burn rate, pipeline potential, and comparisons to similar biotech peers. Market capitalization and enterprise value can provide context, but they should be weighed alongside clinical and regulatory risks.

Trading activity for INMB can vary. As a smaller-cap biotechnology stock, it may have lower average daily volume than large-cap companies. Liquidity can fluctuate based on news and market conditions. To gauge current activity, check the latest volume and bid-ask spread on this page. These metrics help indicate how easily shares can be bought or sold without significant price impact.

Key risks include clinical trial failures, regulatory delays, and the need for additional capital, which can dilute existing shareholders. As a clinical-stage biotech, INMB has no approved products and may never achieve profitability. Competition, intellectual property challenges, and reliance on key personnel are also factors. The stock can be volatile, and share prices may react sharply to pipeline updates or financing news.